A5101529284- Plasma Applications and Diagnostics
- Catalytic Processes in Materials Science
- Radioactive contamination and transfer
- Laser-induced spectroscopy and plasma
- Lung Cancer Treatments and Mutations
- Plasma Diagnostics and Applications
- Nuclear and radioactivity studies
- Ammonia Synthesis and Nitrogen Reduction
- Chemical Synthesis and Characterization
- Caching and Content Delivery
- Synthesis and biological activity
- Catalysis and Hydrodesulfurization Studies
- Gastric Cancer Management and Outcomes
- Advanced Data Storage Technologies
- Industrial Gas Emission Control
- Agriculture, Soil, Plant Science
- Radioactivity and Radon Measurements
- Surface Modification and Superhydrophobicity
- Colorectal Cancer Treatments and Studies
- Catalysis and Oxidation Reactions
- Graphene research and applications
- Advanced Combustion Engine Technologies
- Cancer therapeutics and mechanisms
- Catalysts for Methane Reforming
Korea Institute of Machinery and Materials
2018-2024
Korea Innotech (South Korea)
2022
Korea University of Science and Technology
2018-2020
Korea Institute of Nuclear Safety
2003-2008
Plasma technology is considered a sustainable and clean for the conversion of naturally abundant compounds (i.e., water (H2O) nitrogen gas (N2)) into energy-abundant (e.g., hydrogen (H2), ammonia (NH3)) or chemical feed molecules nitric oxide (NO)). Here, we report plasma catalyst-integrated system production, which can facilitate massive, localized production. This study demonstrates single-step cogeneration H2 oxides (NOx) from H2O in discharge used proceeded via catalytic reduction NOx by...
Plasma-assisted nitrogen fixation is a promising sustainable and clean alternative to the classical Haber-Bosch process. However, high energy consumption low production rate of plasma-assisted limit its application. This study shows that non-thermal (non-equilibrium) enhancement arc plasma significantly reduces fixation. The highest efficiency with NO selectivity observed specific input (SEI). reached at SEI. studied process offers (up 95%) (∼48 GJ per tN) 0.1 kJ L-1 SEI, which much lower...
An energy efficient dry reforming process using a rotating arc plasma is introduced. By virtue of an elongated stable state in arc, thermal efficiency up to 76% and reduction the costs 9.4 5.52 kJ L −1 for reactant conversion syngas production, respectively, are realized. The effects CH 4 /CO 2 molar ratio on cost were also investigated. lowest obtained at ratios 3/7 1 respectively. Moreover, we found that specific input (SEI) 11.2kJ could maximize both CO almost 100%. results presented...
Activated carbon has been extensively utilized to adsorb pollutants generated by industrial activities. There have many attempts efficiently produce activated from spent coffee grounds in the field of environmental technology. In this study, feasibility novel production ground waste using a plasma jet was evaluated. A rotating gliding arc generator designed that used an N2 for carbonization process and CO2 activation process. It confirmed could be carbonized two jets same reactor. The...
Controllability of the kinetic path methane conversion in plasma driven oxidation reaction is investigated. Different geometries a rotating gliding arc reactor are adopted to control paths reaction. Diverging and converging type product different environments view point both time degree thermal activation. In diverging reactor, partial process dominant with high because section facilitates elongate length decrease flow velocity. Thus, convective radiative heat transfer from column reactants...
Abstract EGFR mutations occur in approximately 50% of Asian patients and 20% Caucasian with non-small cell lung cancer (NSCLC). The L858R mutation constitutes half the EGFR-mutated patients, despite receiving first-line or second-line treatment 3rd generation TKI osimertinib, they continue to exhibit a poor prognosis. According real-world analysis, leading resistance mechanism osimertinib is identified as C797S mutation. Furthermore, still associated gastrointestinal skin toxicity, its...
Abstract The L858R activating mutation in Epidermal Growth Factor Receptor (EGFR) accounts for approximately 40% of EGFR-mutant non-small cell lung cancer (NSCLC). These patients receive targeted therapy targeting EGFR mutation. To date all approved tyrosine kinase inhibitors (TKIs) are ATP competitive inhibitors, inevitably lead to drug resistance and disease progress. Osimertinib is a third-generation TKI that selectively inhibits both TKI-sensitizing (L858R) T790M confers acquired first-...